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Summary A tumour model consisting of the highly metastatic mammary 13762 parental line, the non-
metastatic and 6-thioguanine-resistant (TgR) variant line, and two TgR revertant lines (TgRrev, TgRrevM)
that were occasionally metastatic, were used to determine whether the relase of N-acetylneuraminic acid
(NANA) was related to tumour metastasis. For comparative purposes, the occasionally metastatic R3230AC
and the nonmetastatic DMBA8 tumour lines were studied. The NANA was considered to be in bound form,
because acid hydrolysis was required to release it for high-pressure liquid chromatographic analyses. Sera of
animals bearing the 13762 and R3230AC tumours had high levels of bound NANA. No differences were
found in serum NANA levels in animals bearing metastatic or non-metastatic R3230AC tumours. Low levels
of bound NANA were found in animals bearing the other tumour lines regardless of whether metastasis
occurred or not. The experiments in vitro substantiated the in vivo findings. The phenotypic expression of
bound NANA shedding did not correlate well with metastatic potential of the mammary tumour line. Our
analyses suggest that this phenotypic marker cannot be used as a reliable indicator of metastasis.
The shedding of cell-surface components may play
an important role in the process of metastasis. In
both animals and human studies, the level of
shedding is considered to be related to metastatic
ability (Bernacki & Kim, 1977; Black, 1980; Dennis
et al., 1981). The cell components shed can consist
of proteases, adhesion molecules, and antigens
which may impair the immune reponse (Black,
1980; Hynes, 1976). Tumour cells also seem to have
an increased content of sialic acid on cell surface
membranes (Alhadeff & Holzinger, 1982; Black,
1980; Huggins et al., 1980) and such bound sialic
acid has often been detected in the serum of
tumour-bearing hosts and in spent cell-culture
medium (Bemacki & Kim, 1977; Grimm et al.,
1976; Kloppel et al., 1977; Silver et al., 1979). From
these studies it is suggested that shedding of bound
sialic acid may relate to metastasis. However, some
of the difficulties in validating the shedding
hypothesis lies in the fact that (a) in most studies,
the in vitro and in vivo experiments have not been
performed simultaneously, (b) the cells employed,
though exhibiting varying metastatic potential,
generally have different origins and (c) the tumour
cell lines are not from the same syngeneic host. In
this report we have incorporated the above
considerations to determine whether NANA
shedding can be used as a phenotypic marker for
tumour metastasis.
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We recently reported the isolation of a 6-
thioguanine-resistant cell line from the 13762
mammary adenocarcinoma that is not only much
less tumourigenic but also unable to metastasize in
normal rats (Ramshaw et al., 1982). Also, we
detailed the capacity of other rat mammary adeno-
carcinomas to spontaneously metastasize (Hoon et
al., 1983). The availability of these tumour cell
lines, which vary in their metastatic ability,
afforded us the opportunity to study the cell-
surface shedding of bound N-acetylneuraminic acid.
HPLC analysis was used to quantitate the levels of
bound NANA released in specimen hydrolysates. In
this report, we show both in vitro and in vivo that
shedding of bound NANA did not correlate to the
metastatic potential ofthe mammary tumour lines.
Materials and methods
Animals and tumour cell lines
The mammary tumour cell lines used were the
13762, DMBA8, R3230AC, TgR, TgRrev and
TgRrevM, all syngeneic to the F344 rat. The
tumours were grown and handled as previously
reported (Hoon et al., 1983; 1984). The 13762 is a
highly metastatic tumour (100%), whereas the
R3230AC tumour metastasizes in 45 -100% of the
animals. The DMBA8 always grows as a primary
tumour but does not metastasize. A 6-thio-
guanine(TgR)-resistant variant was obtained from
the 13762 cell line, which was found to be poorly
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tumourigenic and non-metastatic (Ramshaw et al.,
1982). From the TgR variant, two more cell lines
were derived, the TgRrev and TgRrevM, which
were metastatic and more tumourigenic than the
TgR line itself. The differences between the
TgRrevM and TgRrev are minor, the former is
more metastatic in the lung tumour colony assay
(Ramshaw et al., 1982). These metastatic derivatives
metastasized in 10 -60% of the animals. The
metastatic ability of these tumour lines was assessed
by injecting the cells into the hind footpad and
assessing lymphatic metastasis in the draining
regional lymph nodes at regular intervals (Hoon et
al., 1983).
Serum specimens
Rats were bled from the tail vein prior to tumour
cell injection (pre-bleed sera) and periodically there-
after (Hoon et al., 1983). For each tumour line
studied two or more experiments had been carried
out.
NANA assay
To assay for in vitro tumour-cell surface shedding,
samples of culture medium were analyzed for
NANA. Only cell cultures in log growth phase with
>95% viability were used in the assays. Since the
13762, TgR, TgRrev, and TgRrevM cells can grow
in suspension, removal of these cells was achieved
by gentle agitation of the flask followed by
pipetting. The R3230AC and DMBA8 cells adhered
firmly to the culture flasks, removal of these cells
required washing the cell monolayer several times
with 0.02 M EDTA in PBS (Ca2 , Mg2 + free,
pH 7.3) for 5min at 37°C, followed by gentle
agitation of the flask to remove the cells. All cells
removed from the culture flasks were then washed
three times in RPMI 1640 medium supplemented
with 5% calf serum, and seeded at a concentration
of 106 cellsml-1 in 60mm tissue culture plates
(Falcon, Oxnard, CA). Two plates were seeded for
each time point, and then incubated at 370C in a
humidified atmosphere of 5% CO2 and 95% air.
At 0, 2, 4, 8, 12, 24 and 32h intervals, cells wre
sampled by first agitating the plate to evenly
disperse the cells, followed by the removal of 1.0ml
aliquots. The samples were centrifuged at 10OOg for
10min at room temperature, and the supernatants
were stored at -8°C until needed. At the end of
each experiment, cells were removed from culture
plates and examined for viability by trypan-blue
and counted (haemocytometer). At this point, cells
were observed to be >85% viable.
Bound NANA both in serum and tissue-culture
medium was analyzed by HPLC. The use of HPLC
for detection of NANA is reliable, selective, and
sensitive (Silver et al., 1979), compared to the
colorimetric procedures (Tuppy & Gottschalk,
1972). The NANA was hydrolyzed from its bound
form by acid treatment as follows: the sample was
diluted 1:20 (v/v) with 0.1 M sulphuric acid, while
the culture medium sample was diluted 1:10 with
1 M sulphuric acid. The diluted samples were then
heated at 80°C for 1 h. Hydrolysates were then
cooled for 15min in a 20°C water bath, and further
diluted 1:1 (v/v) with distilled water. This
minimized the interference of the acid peak during
HPLC analyses on a model 332 gradient system
fitted with model 11OA pumps (Beckman, Berkeley,
CA) and Aminex HPX-87 cation exchange column
(300x7.8mm, Bio-Rad Lab., Richmond, CA). The
NANA in the sample was eluted by a mobile phase
of 0.006M sulphuric acid at a flow rate of
0.65mlmin-1 and pressure of 7 +106Nm 2. The
eluant was monitored at 206nm by a model 100-
40 spectrophotometer (Hitachi, Tokyo, Japan)
fitted with a 5M1 flow cell and an Altex integrator
recorder (Shimadzu Corp., Kyoto, Japan). Samples
at 20 1 were injected into the sampling port via a
Hamilton syringe, preset running time for each
assay was 15min. Each sample was examined at
least twice, and interassay variations where <5%.
The amount of NANA in samples was
determined by comparing the area of the peak with
a standard curve of hydrolyzed NANA (0.15 to
5pmolml-1) established by the same HPLC
procedure. The lowest concentration that could be
detected by this system was 10nmolml-1. The
eulted NANA had a retention time of 7.5min,
while the forerunning acid peak was at 6.0min;
when the tumour serum hydrolysates were assayed,
only an acid and a NANA peak were observed.
When the NANA standard solution was mixed with
tumour serum hydrolysate, there was only one peak
at the NANA retention time. On running the
tumour serum hydrolysate, culture medium
hydrolysate, and standard NANA, in separate runs,
the NANA peak retention times were identical.
Appropriate concentrations of N-acetyl
galactosamine (Sigma, St. Louis, MO) and N-
acetyl-mannosamine (Sigma) were incorporated into
the samples as internal standards. The retention
times did not coincide with the peaks observed with
the respective serum hydrolysates; they were at 8.9
and 11.1 min, respectively. Serum hydrolysates
could be stored at 4°C for 48h without any
significant loss of NANA concentration. Pre-bleed
specimens and the zero time point for culture-
medium specimens for each assay were considered
as baseline or background levels. The values
obtained after this point were expressed in terms of
increases over baseline levels. Normal control serum
specimens taken at random diurnal periods for sex-
age-matched rats were 2.95+0.05 s.e. ,molml-1I
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specimens that were not hydrolyzed by acid had
undetectable levels of free NANA. In culture
specimens, the main source of background level of
bound NANA was from the calf serum, which was
327+11.1 s.e.nmolmml.
Statistics
The Student t-test was used for statistical analysis.
In the comparison of serum specimens, the
maximum level of bound NANA obtained for each
tumour-bearing animal was used.
Results
Animal studies
All animals injected in the hind footpad with 106 or
5 x 106, 13762 cells developed large primary
tumours (x=7mm diam.) and palpable lymph
nodes by day 25. The 13762 tumour growth was
rapid, and the size increased in a linear fashion.
Concomitantly, the bound NANA in the sera of
these tumour-bearing animals increased by Day 5
and started to plateau by Day 10 (Figure IA).
These findings suggested that the increase of bound
NANA in sera of 13762 tumour-bearing animals is
related to the rapid growth and/or metastatic
ability of the tumour. In comparison, the sera of
TgR, TgRrev, and TgRrevM tumour-bearing
animals (Figure 1B) were analyzed and found to
contain -3-4 times less bound NANA than that in
the 13762 tumour-bearing animals. The differences
in NANA between 13762 and the other tumours
studied were not considered to be due to tumour
load, as most of the animals had developed








the experiment. Because TgR, TgRrev, and
TgRrevM cells were poorly tumourigenic, it was
necessary to inject 5 x 106 cells to produce tumours.
In the TgR tumour-bearing animals, the growth of
the primary tumour progressed in a linear fashion,
and by Day 75, the tumour had reached a size of
11.0mm x diam., at which time the animals were
sacrificed. However, palpable lymph node
metastases were not detected in these animals, and
careful histological examination of the draining
lymph nodes also showed no evidence of micro-
metastasis. In contrast, 3 out of 5 animals injected
with TgRrev cells had. palpable lymph node
metastasis at the termination of the experiment. As
for the TgRevM tumour-bearing animals, 2 of the 4
had palpable lymph node metastasis. Again, no
micrometastases were detected on histological
examination of non-palpable lymph nodes.
Although tumour growth increased in a linear
fishion in both the TgRrev and TgRrevM tumour-
bearing animals, the amount of NANA in the sera
of these animals did not increase proportionally. No
significant differences occurred in bound NANA
levels of animals bearing metastatic TgRrev and
TgRrevM tumours compared to those animals
bearing non-metastatic tumours.
In R3230AC tumour-bearing animals, the levels
of bound NANA in sera were low at the early
stages of primary tumour growth (Figure 2);
however, after day 54 post tumour cell injection
(106 cells) the levels increased as the growth of the
primary tumours increased rapidly. The experiment
was terminated on day 81 because of the size of the
primary tumours (x= 19.0mmdiam.). There were no
significant differences in the levels of bound NANA
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Figure 1 Increased levels of bound NANA in sera (A) of rats (5) inoculated with 13762 cells (0); (B) rats (5)
inoculated with TgR cells (0); rats (5) inoculated with TgRrev cells (A) and rats (4) inoculated with TgRrevM
cells (0). Points represent mean values; bars, s.e. Normal sera level of bound NANA was at 2.95










Figure 2 Increased levels of bound NANA in sera of
rats inoculated with R3230AC tumour cells. Rats were
divided into 3 groups at the termination of the
experiment; these groups are: rats (9) with no
metastasis (0); rats (6) with micrometastasis (-); and
rats (4) with macrometastasis (0). Points represent
mean values; bars, s.e. Normal serum level of bound
NANA was at 2.95+0.05 s.e. jmolml-'. Values shown
on graph were obtained after normal sera levels were
subtracted.
amongst the R3230AC tumour-bearing animals.
The peak levels of bound NANA (above norm) in
animals with micrometastasis, macrometastasis, or
no metastasis were 5.09, 3.82 and 4.04Mmolml-1,
respectively. Animals injected s.c. in the footpad
with 106 DMBA8 cells developed tumours rapidly.
Tumour growth increased in a linear fashion, and
on day 56, all animals were sacrificed due to
cachectic conditions and tumour size (diam. x
= 10.0mm). There was no evidence of either macro-
or micrometastasis in the tumour-draining lymph
nodes of these animals. The level of bound NANA
in sera of DMBA8 tumour-bearing animals was low
(Table II) in comparison with the levels for the
R3230AC and 13762 tumour-bearing animals
(Table I). Overall, the growth rate of the tumour
lines did not correlate with bound NANA levels in
sera.
Cell culture studies
To support the above in vivo studies, the tumour
cell lines were examined for in vitro shedding using
cell-culture conditions. Without acid hydrolysis, no
NANA was detected in the spent culture medium
of all cell lines tested. However, upon acid hydro-
lysis, the culture medium of the 13762 cells
contained more bound NANA than the other
tumour cells (Figure 3A). Also, the amount of
bound NANA in the medium, presumably shed by
Table I Bound NANA levels in sera and culture medium and metastatic
potential of tumour lines
Mean ofmax. Mean ofbound
bound NANA NANA in General
Metastatic in serab culture mediumc bound NANA
Cell lines potentiaP (pmolml-') (nmolml 1) leveld
13762 ++ ++ + 7.50 350 High
TgR 0.72 120 Low
TgRrev + + 1.44 90 Low
TgRrevM + + + 0.65 90 Low
R3230AC + + + + 4.32 210 Intermediate
DMBA8 1.85 100 Low
aAssessed by the ability of cells in a primary footpad tumour to metastasize to
the lymph nodes and to the lungs (see Materials and Methods). + + + + +, high;
-, none.
bMean of maximum bound NANA level in sera of individual rats in each group.
Normal serum levels have been subtracted from values. 13762 versus TgR, TgRrev
and TgRrevM; 13762 versus R3230AC; 13762 versus DMBA8; and R3230AC versus
DMBA8 were all P<0.001.
cMean of bound NANA in spent culture medium of 24h cell cultures. Values
were obtained after calf serum culture medium bound NANA was subtracted.
13762 versus TgR, TgRrev and TgRrevM, P<0.03.
'Comparative ranking based on general bound NANA released in spent culture
medium and levels in sera of tumour-breaing rats; comparison amongst the
tumour lines studied.RELEASE OF NANA AND METASTASIS 779
Table II Bound NANA in sera of DMBA8
tumour-bearing animals
Bound NANA'







Increased levels of bound NANA in sera of
rats (12) inoculated with 106 DMBA8 cells.
aNumbers in brackets represent bound
NANA level after subtraction of pre-bleed level.
the 13762 cells, increased in a linear fashion.
Comparatively, the amount of bound NANA
(above norm) in the media of TgR TgRrev, and
TgRrevM tumour cells was low (Figure 3A, Table
I). In the R3230AC cultures, the amount of bound
NANA increased steadily in linear fashion (Figure
3B). In general the R3230AC cells shed more
bound NANA than all the other tumour lines
except the 13762 tumour cells. The level of bound
NANA in DMBA8 cell culture medium was similar
to the TgR variants. At the completion of the
experiments, cell growth was determined for all the
tumour lines. Overall, the cell population for the
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32h. This suggested that bound NANA release was
not simply related to tumour line growth rates
Discussion
In this study, shedding of bound NANA by
mammary tumour lines was investigated using both
in vitro and in vivo conditions. We asked the
question does shedding of bound NANA correlate
to the metastatic potential of tumour cells? In these
studies the sera of animals bearing the highly
metastatic 13762 tumour contained greater amounts
of bound NANA than the sera of animals bearing
other tumours. The in vitro findings also supported
the in vivo findings, in that the 13762 cells shed high
levels of bound NANA into the culture medium. In
comparison the serum levels of bound NANA in
TgR tumour-bearing animals were low, similarly
the TgR cells in culture released small amounts of
bound NANA. These results did show that there
was a difference in NANA shedding between
metastatic and nonmetastatic tumour cells of the
same origin.
However the TgRrev and TgRrevM tumours
which were found to be occasionally metastatic,
had only low levels of bound NANA in sera and in
spent culture medium. The metastatic TgR variants
were expected to shed more bound NANA than the
TgR variant. One reason for the low level of
shedding by these metastatic variants is that like
other tumours they contain a population of cells
Time (h)
Figure 3 Presence of bound NANA in medium of cell cultures. Spent cell culture medium was analyzed from
(A) 13762 cells (0), TgR variant cells (A), TgRrev cells (0) and TgRrevM cells (0); (B) R3230AC cells (0)
and DMBA8 cells (A). Each point represents the mean value of duplicate determinations and the mean of 2
cultures. The s.e. of each point was insignificant to record on the graph. The calf serum culture medium (cell
free) bound NANA level was at 327+11.1 s.e. ,molml 1 (Oh). Values shown on graphs were obtained after
calf serum culture medium bound NANA was subtracted.780 D.B.S HOON et al.
that are heterogeneous in their metastatic ability. In
such a situation, the presence of effective metastatic
potentials may be very low, as suggested by a
recent study on experimental metastasis using
tumour lines of various metastatic ability (Harris et
al., 1982). If this is true, then the level of bound
NANA shed may depend on the number of
metastatic subpopulations within the tumour that
are shedding. For tumours such as the metastatic
TgR variants one would expect much lower
numbers of subpopulations capable of metastasizing
as compared to the 13762. It is not known why
tumour lines with variable metastatic ability such as
the TgR revertants metastasize in some animals and
not in others. The low level of bound NANA
release is possibly related to the TgR revertants
instability. In general for the 13762-TgR cell model
the level of bound NANA shedding did not
correlate with the metastatic potential of the
tumour cells.
In the in vitro studies R3230AC cells shed
significantly large amounts of bound NANA
compared to the non-metastatic tumour lines. For
the in vivo studies, the level of bound NANA in
sera of R3230AC tumour-bearing animals was high.
The level of bound NANA in these tumour-bearing
animals correlated to the metastatic potential of the
R3230AC tumour. However, in the tumour-bearing
animals there was no direct correlation between
elevated serum bound NANA and the presence of
metastasis; both non-metastatic and metastatic
tumour-bearing animals had similar serum bound
NANA levels. The study with the R3230AC
tumour does suggest that NANA shedding is not a
phenotypic marker for the presence ofmetastasis.
An interesting characteristic of the R3230AC
tumour is that it metastasizes occasionally. There is
a possibility that all R3230AC cells release bound
NANA; however the establishment of metastasis
does not always occur in all animals due to a host
or other cell characteristic(s).
The levels of bound NANA detected in blood
may be affected by host factors which can play a
role in their rapid removal. Bound NANA in blood
could be removed by the reticuloendothelial system
(Baldwin & Robins; 1977) or by specific antibodies
(Kim, 1979). Thus one has to be cautious in
interpreting in vivo results, such as in the R3230AC
tumour model where bound NANA levels were low
at early stages of growth. At this stage the host
system may have been effective in removing the
bound NANA from the blood.
A portion of the bound NANA in tumour serum
hydrolysates may be of host origin, however, this
has yet to be determined. Various secondary factors
such as a1-acid glycoprotein from the liver
may be elevated in the blood in response to
tumour or more particularly metastasis to liver
(Chandrasekaran et al; 1984). In our tumour models
there was no metastasis to the liver and direct
correlation between rise in serum bound NANA
and metastasis. Recently, a report by Huggins et al.
(1980), showed that a soluble high mol. wt sialo-
glycoprotein is shed by 13762 ascites cells. The
release of bound NANA by tumour cells may be
associated with contact of tumour cells and blood
enzymes. If this does occur then the extent of
vascularization of the tumour may play an
important factor in the serum bound NANA levels
as well as metastasis (Sugarbaker, 1979). Tumour
cells have been shown to contain plasminogen
activator which is capable of activating the blood
proenzyme plasminogen to plasmin (Ramshaw et
al., 1982). The activation of plasmin to proteolytic
enzyme near the tumour cell surface may be
responsible for cell surface shedding (Unkeless et al.,
1979). Previously we showed that high levels of
plasminogen activator were released by 13762 cells,
but only low levels were released by TgR cells
(Ramshaw et al., 1982). Coincidently, the
plasminogen activator activity of 13762 and the
TgR derivatives directly relates to the level of
bound NANA released, but does not correlate with
metastatic ability.
Of the several mammary adenocarcinoma cell
lines studied, the relase of bound NANA did not
appear to be convincing related to the tumours'
metastatic potential. In this report comparisons
have been made with (a) animals bearing tumours
with no or poor metastatic potential derived from a
highly metastatic parent tumour line, (b) animals
bearing the same tumour with no, micro and macro
metastasis and (c) animals with different tumour
lines not of the same origin but of similar histology.
The tumour size did not correlate with the level of
bound NANA in sera. Although bound NANA
shedding may not be a marker of metastasis it may
still play a role in metastasis in a synergistic
manner with other tumour cell factors. The
shedding of bound NANA may possibly be used as
a marker for presence of tumour. Recent studies by
Steck & Nicolson (1983) suggest that the
quantitative changes on the cell surface glyco-
proteins of the 13762NF MAT rather than the
qualitative changes are associated with metastatic
behaviour. Further studies will involve
characterization of the shed bound NANA carbo-
hydrate components.
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